Quantib® Prostate is currently 510(k) cleared by the FDA for distribution in the US. This product has been proven to conform to all requirements of the European Medical Device Regulations (2017/745) and is available in the EU and other countries.
1 Taneja, S. S. et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).
2 Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822.
3 Andrew B. Rosenkrantz, M. et al. ACR - Prostate MRI Model Policy. Available at: https://www.acr.org/-/media/ACR/Files/Advocacy/AIA/Prostate-MRI-Model-Policy72219.pdf. (Accessed: 7th May 2020)
4 Mottet, N. et al. European Association of Urology - Prostate Cancer. 2020 Available at: https://uroweb.org/guideline/prostate-cancer/. (Accessed: 7th May 2020)
No more switching between PACS, PSA density calculation feature and PI-RADS support; Quantib® Prostate offers one workflow including all essential prostate MRI reading features.
Semi-automated combination of bi-parametric data supports ROI determination and enables prostate lesion evaluation. AI-bolstered segmentation allows for easy and fast determination of lesion volume.
After prostate MRI assessment, a customized report is created including PSA density, quantified volumes, PI-RADS v.2.1 scoring and key images of suspicious regions.
Quantib® Prostate is currently 510(k) cleared by the FDA for distribution in the US. This product has been proven to conform to all requirements of the European Medical Device Regulations (2017/745) and is available in the EU and other countries.
The benefits of AI for radiology are numerous. Tim Leiner, Professor of Radiology at the Department of Radiology, Utrecht University Medical Center in Utrecht, The Netherlands discusses how AI-powered tools can support the radiologists in their daily clinical workflow